← boardnext 2026-12-31
ESLA
Estrella Biopharma, Inc.distress 4/10 · elevated risk$0.79+4%today-74% from 52w high
Lead: Lymphoma · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
+16%
Price & events
-16.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.8%
1D
+6.5%
1W
-21.0%
1M
-53.8%
3M
-21.8%
6M
-12.2%
1Y
-49.0%
2Y
—
5Y
-91.9%
All
Overview
- Market Cap
- $34.00M
- Volume
- 1.16K
- 52 Week Range
- $0.74 – $3.05
- Total Shares
- 43.03M
- Float Shares
- 14.11M
- Short %
- 0.53%
- % Held by Insiders
- 60.61%
- % Held by Institutions
- 12.15%
- RVOL
- 0.03x
- Beta
- 0.86
Pipeline stages · 1 programs
EB103
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 1/2 | EB103 | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | — | recruiting |
Catalyst news & presentations · 1
- first patient dosed on July 31, 2024trial initiationsecondaryPhase 1/2EB103 · Dosing of first patient in STARLIGHT-1 Phase I/II trial for EB103 autologous T-cell therapy.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 43,034,228 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $12 (+1419% upside) · 1 analysts
- 2026-02-09D. Boral CapitalBuy
- 2026-01-28D. Boral CapitalBuy
- 2025-11-03D. Boral CapitalBuy
- 2025-08-12D. Boral CapitalBuy
- 2025-06-03D. Boral CapitalBuy
- 2025-05-29D. Boral CapitalBuy
Competitors — Lymphoma
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- ALLOAllogene Therapeutics, Inc.$623M · D5
- ADILADIAL PHARMACEUTICALS, INC.$6M · D6
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
- 2026-07-19Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
- 2026-07-09Investigation launched into Estrella Immunophar... - Pluang
- 2026-07-09Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low Volatility - Demand Zone - dars.gov.et
- 2026-07-09Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low Volatility - Calendar Spread Trade - dars.gov.et
- 2026-07-09ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire
- 2026-06-30Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks
- 2026-06-21Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.